COPD Drugs Linked To Increased Cardiovascular Health Risks: Study
Some COPD treatments can significantly increase the risk of severe heart problems after just one month of treatment, according to the findings of a new study.…
«
»
Some COPD treatments can significantly increase the risk of severe heart problems after just one month of treatment, according to the findings of a new study.…
The FDA is removing a black box warning from certain asthma inhalers, saying that evidence shows they do not carry the increased risk of severe asthma side effects and death that older research indicated.…
The findings of a new study resurrects concerns that some long-acting inhalers used to treat chronic pulmonary obstructive disease (COPD), such as Spiriva and Serevent, could increase the risk of serious heart problems. …
A new study suggests a link between specific birth defects and asthma medication use during pregnancy, raising concerns about the safety of popular drugs like Advair and Symbicort among expectant mothers. …
Federal drug regulators have ordered that new studies be done to examine potential safety problems with a number of asthma drugs, including Advair, Symbicort, Dulera and Foradil. …
Federal regulators have moved to restrict the use of Advair, Symbicort, Foradil and Serevent, after determining that side effects of the asthma drugs may increase the risk of severe asthma problems and death in both adults and children.…
An FDA advisory panel, which met Wednesday and Thursday to review long-acting asthma inhaler risks, has indicated that Foradil and Serevent should no longer be approved for treatment of asthma. However, the panel indicated that the more popular asthma drugs Advair and Symbicort, which combine Serevent and Foradil respectively with inhaled steroids, should remain available for adults and children, despite the increased risk of severe asthma attacks and death.…
Several FDA officials have warned that because side effects of Advair, Serevent, Foradil and Symbicort may increase the risk of death, an FDA advisory panel should recommend that approval to use the drugs for treatment of asthma should be withdrawn or severely limited.…